Evaluation of the Serum Level of Vascular Endothelial Growth Factor in Patients with Beta-Thalassemia Major and Sickle/Beta-Thalassemia, and its Correlation with Clinical and Laboratory Parameters

BACKGROUND: The most prevalent inherited disorders of red blood cells are hemoglobinopathies, with thalassemia and sickle cell diseases (SCDs) being the most common. In SCD and thalassemia major, angiogenesis has been identified as a substantial contributor to vascular-mediated tissue damage. Vascul...

Full description

Bibliographic Details
Main Authors: Sara Anmar Abdul Mohsin, Israa M Al-Bayaa, Ihsan Mardan Al-Badran
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2023-01-01
Series:Journal of Applied Hematology
Subjects:
Online Access:http://www.jahjournal.org/article.asp?issn=1658-5127;year=2023;volume=14;issue=2;spage=115;epage=121;aulast=
_version_ 1797738673696931840
author Sara Anmar Abdul Mohsin
Israa M Al-Bayaa
Ihsan Mardan Al-Badran
author_facet Sara Anmar Abdul Mohsin
Israa M Al-Bayaa
Ihsan Mardan Al-Badran
author_sort Sara Anmar Abdul Mohsin
collection DOAJ
description BACKGROUND: The most prevalent inherited disorders of red blood cells are hemoglobinopathies, with thalassemia and sickle cell diseases (SCDs) being the most common. In SCD and thalassemia major, angiogenesis has been identified as a substantial contributor to vascular-mediated tissue damage. Vascular endothelial growth factor (VEGF) is the master regulator of angiogenesis. This study aims to assess the circulating level of serum VEGF in beta-thalassemia (β-thal) and sickle β-thal patients and also to explore the correlation with clinical and laboratory data. PATIENTS, MATERIALS AND METHODS: This is a cross-sectional study conducted on 80 individuals, clinical data were gathered, complete blood count, serum ferritin, and serum VEGF tests were done. RESULTS: Patients' age ranged from 1.5 to 17.5 years, males formed (70%). Platelet count was significantly higher in β-thal compared to sickle/β-thal (S/β-thal) patients, with a P = 0.015. Mean serum ferritin in patients was significantly higher in β-thal compared to S/β-thal patients, P < 0.001. Patients' serum VEGF levels were noticeably higher than controls with P = 0.01. Strong positive correlation of serum VEGF with platelet count among the patients (r = 0.603, P < 0.001). A significant positive correlation was observed between serum VEGF and the age of starting chelation therapy in thalassemic patients (r = 0.475, P = 0.006). CONCLUSIONS: Serum VEGF levels were significantly higher in patients compared to healthy controls, and there is a significant positive correlation between serum VEGF levels and the age at which iron chelation therapy was initiated as well as between serum VEGF levels and platelet counts in patients.
first_indexed 2024-03-12T13:46:12Z
format Article
id doaj.art-91139123dbe24b9cb1f5284e68f6567c
institution Directory Open Access Journal
issn 1658-5127
language English
last_indexed 2024-03-12T13:46:12Z
publishDate 2023-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Journal of Applied Hematology
spelling doaj.art-91139123dbe24b9cb1f5284e68f6567c2023-08-23T08:58:20ZengWolters Kluwer Medknow PublicationsJournal of Applied Hematology1658-51272023-01-0114211512110.4103/joah.joah_98_22Evaluation of the Serum Level of Vascular Endothelial Growth Factor in Patients with Beta-Thalassemia Major and Sickle/Beta-Thalassemia, and its Correlation with Clinical and Laboratory ParametersSara Anmar Abdul MohsinIsraa M Al-BayaaIhsan Mardan Al-BadranBACKGROUND: The most prevalent inherited disorders of red blood cells are hemoglobinopathies, with thalassemia and sickle cell diseases (SCDs) being the most common. In SCD and thalassemia major, angiogenesis has been identified as a substantial contributor to vascular-mediated tissue damage. Vascular endothelial growth factor (VEGF) is the master regulator of angiogenesis. This study aims to assess the circulating level of serum VEGF in beta-thalassemia (β-thal) and sickle β-thal patients and also to explore the correlation with clinical and laboratory data. PATIENTS, MATERIALS AND METHODS: This is a cross-sectional study conducted on 80 individuals, clinical data were gathered, complete blood count, serum ferritin, and serum VEGF tests were done. RESULTS: Patients' age ranged from 1.5 to 17.5 years, males formed (70%). Platelet count was significantly higher in β-thal compared to sickle/β-thal (S/β-thal) patients, with a P = 0.015. Mean serum ferritin in patients was significantly higher in β-thal compared to S/β-thal patients, P < 0.001. Patients' serum VEGF levels were noticeably higher than controls with P = 0.01. Strong positive correlation of serum VEGF with platelet count among the patients (r = 0.603, P < 0.001). A significant positive correlation was observed between serum VEGF and the age of starting chelation therapy in thalassemic patients (r = 0.475, P = 0.006). CONCLUSIONS: Serum VEGF levels were significantly higher in patients compared to healthy controls, and there is a significant positive correlation between serum VEGF levels and the age at which iron chelation therapy was initiated as well as between serum VEGF levels and platelet counts in patients.http://www.jahjournal.org/article.asp?issn=1658-5127;year=2023;volume=14;issue=2;spage=115;epage=121;aulast=sickle β-thalassemiavascular endothelial growth factorβ-thalassemia major
spellingShingle Sara Anmar Abdul Mohsin
Israa M Al-Bayaa
Ihsan Mardan Al-Badran
Evaluation of the Serum Level of Vascular Endothelial Growth Factor in Patients with Beta-Thalassemia Major and Sickle/Beta-Thalassemia, and its Correlation with Clinical and Laboratory Parameters
Journal of Applied Hematology
sickle β-thalassemia
vascular endothelial growth factor
β-thalassemia major
title Evaluation of the Serum Level of Vascular Endothelial Growth Factor in Patients with Beta-Thalassemia Major and Sickle/Beta-Thalassemia, and its Correlation with Clinical and Laboratory Parameters
title_full Evaluation of the Serum Level of Vascular Endothelial Growth Factor in Patients with Beta-Thalassemia Major and Sickle/Beta-Thalassemia, and its Correlation with Clinical and Laboratory Parameters
title_fullStr Evaluation of the Serum Level of Vascular Endothelial Growth Factor in Patients with Beta-Thalassemia Major and Sickle/Beta-Thalassemia, and its Correlation with Clinical and Laboratory Parameters
title_full_unstemmed Evaluation of the Serum Level of Vascular Endothelial Growth Factor in Patients with Beta-Thalassemia Major and Sickle/Beta-Thalassemia, and its Correlation with Clinical and Laboratory Parameters
title_short Evaluation of the Serum Level of Vascular Endothelial Growth Factor in Patients with Beta-Thalassemia Major and Sickle/Beta-Thalassemia, and its Correlation with Clinical and Laboratory Parameters
title_sort evaluation of the serum level of vascular endothelial growth factor in patients with beta thalassemia major and sickle beta thalassemia and its correlation with clinical and laboratory parameters
topic sickle β-thalassemia
vascular endothelial growth factor
β-thalassemia major
url http://www.jahjournal.org/article.asp?issn=1658-5127;year=2023;volume=14;issue=2;spage=115;epage=121;aulast=
work_keys_str_mv AT saraanmarabdulmohsin evaluationoftheserumlevelofvascularendothelialgrowthfactorinpatientswithbetathalassemiamajorandsicklebetathalassemiaanditscorrelationwithclinicalandlaboratoryparameters
AT israamalbayaa evaluationoftheserumlevelofvascularendothelialgrowthfactorinpatientswithbetathalassemiamajorandsicklebetathalassemiaanditscorrelationwithclinicalandlaboratoryparameters
AT ihsanmardanalbadran evaluationoftheserumlevelofvascularendothelialgrowthfactorinpatientswithbetathalassemiamajorandsicklebetathalassemiaanditscorrelationwithclinicalandlaboratoryparameters